employee
Novosibirsk, Russian Federation
employee
Novosibirsk, Russian Federation
employee
Novosibirsk, Russian Federation
UDK 33 Экономика. Экономические науки
The vaccine market is one of the most attractive and fast-growing segments of the global pharmaceutical market. The increasing interest in the development and creation of new vaccines caused a significant influx of investment in research activities, which did not slow down the impact on the further development of the market. The present research featured the global market for COVID-19 vaccines. The research objective was to assess the state of the COVID vaccine market as a new segment of the global vaccine market. The work uses statistical materials of the World Health Organization, the International Federation of Pharmaceutical Manufacturers and Associations, Statista, Rosstat, and Rospotrebnadzor, as well as methods of general logical, analytical, statistical, and empirical analyses. The demands for the global COVID-19 vaccine market are currently enormous, and the global demand for COVID-19 vaccines can range from 10 to 14 billion doses per year, depending on the desired level of coverage and the need for re-vaccination. The current leading manufacturers of vaccines against COVID-19 are Pfizer (USA) / BioNTech (Germany), Sinovac Biotech (China), AstraZeneca (UK), Moderna (USA), and Sinopharm (China). In terms of production volumes, they are significantly inferior to N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology (Russia). The prevalence of World Health Organization-approved vaccines differs by country: (1) Vaxzevria vaccine (AstraZeneca) was approved in 101 countries, (2) Pfizer / BioNTech – in 85 countries, (3) Moderna – in 46 countries, (4) Sinopharm vaccines – 42 countries, (5) Janssen (Johnson & Johnson) – in 41 countries, (6) Covishield (Serum Institute of India) – in 40 countries. As of May 20, 2021, the Russian Sputnik V was registered in 68 countries. For all manufacturers, the expansion of production provokes the same problems, which are mostly connected with the supply of culture media, filters, disposable consumables, and equipment, especially during peak demand.
vaccines, healthcare, pharmaceutical market, immunobiological drugs market, infectious diseases, coronavirus infection, COVID-19 pandemic, investments
1. Ortega-Sanchez I. R., Molinari N.-A. M., Fairbrother G., Szilagyi P. G., Edwards K. M., Griffin M. R., Cassedy A., Poehling K. A., Bridges C., Staat M. A. Indirect, out-of-pocket and medical costs from influenza-related illness in young children. Vaccine, 2012, 30(28): 4175-4181. DOI:https://doi.org/10.1016/j.vaccine.2012.04.057
2. Andrianova E. P., Prikazchikova Yu. V. About current trends of the global and Russian vaccine markets' development. Sovremennye nauchnye issledovaniia i innovatsii, 2016, (5): 163-166. (In Russ.)
3. Akimova Yu. I., Protsenko M. V. The Russian market of vaccines: specificity, the dynamics of development and prospects. Sovremennaia organizatsiia lekarstvennogo obespecheniia, 2013, (3): 10-22. (In Russ.)
4. Trukhin V. P., Narkevich I. A., Basakina I. I., Barabanova A. I. Marketing analysis of the Russian immunobiological medicines market within the framework of vaccines. Medicinskij vestnik Bashkortostana, 2019, 14(3): 47-50. (In Russ.)
5. Li T., Zhang T., Gu Y., Li S., Xia N. Current progress and challenges in the design and development of a successful COVID-19 vaccine. Fundamental Research, 2021, 1(2): 139-150. DOI:https://doi.org/10.1016/j.fmre.2021.01.011
6. El Bagoury M., Tolba M. M., Nasser H. A., Jabbar A., Elagouz A. M., Aktham Y., Hutchinson A. The find of COVID-19 vaccine: challenges and opportunities. Journal of Infection and Public Health, 2020, 14(3): 389-416. DOI:https://doi.org/10.1016/j.jiph.2020.12.025
7. Rawat K., Kumari P., Saha L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. European Journal of Pharmacology, 2021, 892. DOI:https://doi.org/10.1016/j.ejphar.2020.173751
8. Verbeke R., Lentacker I., De Smedt S. C., Dewitte H. The dawn of mRNA vaccines: the COVID-19 case. Journal of Controlled Release, 2021, 333: 511-520. DOIhttps://doi.org/10.1016/j.jconrel.2021.03.043
9. Wouters O. J., Shadlen K. C., Salcher-Konrad M., Pollard A. J., Larson H. J., Teerawattananon Y., Jit M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet, 2021, 397(10278): 1023-1034. DOI:https://doi.org/10.1016/S0140-6736(21)00306-8
10. Dos Santos W. G. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomedicine & Pharmacotherapy, 2021, 136. DOI:https://doi.org/10.1016/j.biopha.2021.111272
11. Forman R., Shah S., Jeurissen P., Jit M., Mossialos E. COVID-19 vaccine challenges: What have we learned so far and what remains to be done? Health policy, 2021, 125(5): 553-567. DOI:https://doi.org/10.1016/j.healthpol.2021.03.013
12. Singh J. A., Upshur R. E. G. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. The Lancet Infectious Diseases, 2021, 21(4): E103-E109. DOI:https://doi.org/10.1016/S1473-3099(20)30923-3
13. Gramacho W. G., Turgeon M. When politics collides with public health: COVID-19 vaccine country of origin and vaccination acceptance in Brazil. Vaccine, 2021, 39(19): 2608-2612. DOI:https://doi.org/10.1016/j.vaccine.2021.03.080
14. Jones M. R., Viswanath O., Peck J., Kaye A. D., Gill J. S., Simopoulos T. T. A brief history of the opioid epidemic and strategies for pain medicine. Pain and therapy, 2018, 7(1): 13-21. DOI:https://doi.org/10.1007/s40122-018-0097-6
15. Marks J. H. Lessons from corporate influence in the opioid epidemic: toward a norm of separation. Journal of Bioethical Inquiry, 2020, 17(1): 173-189. DOI:https://doi.org/10.1007/s11673-020-09982-x
16. Latkin C. A., Dayton L., Yi G., Konstantopoulos A., Boodram B. Trust in a COVID-19 vaccine in the U.S.: a social-ecological perspective. Social Science & Medicine, 2021, 270. DOI:https://doi.org/10.1016/j.socscimed.2021.113684
17. Lazarus J. V., Ratzan S. C., Palayew A., Gostin L. O., Larson H. J., Rabin K., Kimball S., El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nature Medicine, 2021, 27(2): 225-228. DOI:https://doi.org/10.1038/s41591-020-1124-9
18. Sharun K., Dhama K. COVID-19 vaccine diplomacy and equitable access to vaccines amid ongoing pandemic. Archives of Medical Research, 2021. DOI:https://doi.org/10.1016/j.arcmed.2021.04.006
19. So A. D., Woo J. Achieving path-dependent equity for global COVID-19 vaccine allocation. Med, 2021, 2(4): 373-377. DOI:https://doi.org/10.1016/j.medj.2021.03.004
20. Prozherina Yu. Trend in global pharmaceutical market: COVID. Remedium, 2020, (9): 23-24. (In Russ.) DOI:https://doi.org/10.21518/1561-5936-2020-9-23-24
